/
Vaxart Biosciences, Inc. was originally incorporated in California under the name West Coast Biologicals, Inc. in March 2004 and changed its name to Vaxart, Inc. ( Private Vaxart ) in July 2007, when it reincorporated in the state of Delaware. On February 13, 2018, Private Vaxart completed a reverse merger (the Merger ) with Aviragen Therapeutics, Inc. ( Aviragen ), pursuant to which P…
Operating margin is thin at 7.62%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 726.7% YoY with margins expanding 238.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$256M
▲ +726.7% YoY
Net Income (TTM)
$37M
▲ +124.4% YoY
Op. Margin
14.94%
▲ +238.6pp YoY
ROIC
52.09%
▲ +88.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$15M
▲ +116.7% YoY
Op. Cash Flow (TTM)
$15M
▲ +117.2% YoY
Net Debt
-$53M
Net Cash Position
Cash & Equiv.
$61M
5Y CAGR: +125.8%
Continue Research